VIVOLTA appoints Denis Leissing as CEO alongside Rudy Mareel as Non-Executive Chairman

– NETHERLANDS, Waalre –  VIVOLTA, a leading global player in the contract development and manufacturing of electrospun medical products, today announced the appointment of Denis Leissing as CEO, taking over from founder and interim CEO Ramon Solberg who remains as CTO.

The company also announced the appointment of current Non-Executive Director Rudy Mareel as the new Non-Executive Chairman of the Board, succeeding Fennemiek Gommer.

About Denis Leissing

Denis Leissing brings decades of international experience in the medical device and contract manufacturing sectors, with a proven track record of successfully leading organizations through transformative, high-growth phases. In his previous role as CEO of Mediliant, a Swiss medical device manufacturing organization serving the world’s largest medical device brands, Mr. Leissing demonstrated a keen understanding of the global medical device industry and trends, while effectively leading the company to fulfill its vision – one similar to VIVOLTA’s aim to be the trusted partner in contract development and manufacturing of electrospun medical products.

Denis Lessing said: “VIVOLTA is a truly global leader in the medical electrospinning sector, and it is an honor to be appointed as CEO. I am committed to driving VIVOLTA’s strategy onwards, transforming our clients’ development projects into fully scalable commercial products over the coming years.”

Denis Leissing holds a master’s degree in mechanical engineering from ECAM Lyon and an executive MBA from HEC Paris.

About Rudy Mareel

Rudy Mareel is a seasoned executive in the healthcare industry, bringing a wealth of expertise and experience. With a distinguished career in senior leadership roles in Europe and the US and an in-depth understanding of the global healthcare market, he led Polyganics, a Dutch regenerative medicine company, to a successful acquisition by Regenity Biosciences last year. With his extensive experience serving on both Executive and Non-Executive boards of various healthcare companies, he will play a pivotal role in guiding the Board of Directors and supporting the company’s strategic initiatives.


VIVOLTA is a world leader in developing and manufacturing electrospun medical products. Utilizing its proprietary, fully automated MediSpin production platform, VIVOLTA supports its clients in realizing electrospun medical solutions that guide the body to heal itself. VIVOLTA’s medical electrospinning solutions apply to a broad array of high-value therapeutic areas with unmet clinical needs, such as cardiovascular implants, soft tissue repair, orthopedic sports medicine, and drug delivery.

The Company, formerly IME Medical Electrospinning, is a pioneer and global leader in the electrospinning sector, having contributed significantly to the first ASTM (American Society for Testing and Materials) standard for fiber-based medical scaffolds (F3519-21), published in 2021.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.